The article documents how, and why, we are losing the war against these powerful microbes. Hospitals and doctors have overused "last-resort" antibiotics, leading to...
This week's New Yorker has a sobering piece by Recanati professor of medicine Jerome Groopman on drug-resistant "superbugs."
The article documents how, and why, we are losing the war against these powerful microbes. Hospitals and doctors have overused "last-resort" antibiotics, leading to new microbial strains resistant even to these drugs; meanwhile, many pharmaceutical companies are no longer developing new antibiotics. "Drug companies are looking for blockbuster therapies that must be taken daily for decades," he writes. "Antibiotics are used to treat infections, and are therefore prescribed only for days or weeks," after which the patient (or the patient's insurance) stops paying, and the drug company stops making money.
Fingering medical tourism as a contributing factor—not only patients, but also the bacteria in their systems, are transported to far-flung hospitals—Groopman finds that conditions have aligned to create the perfect storm. But he also offers a glimmer of hope, outlining new avenues of research being explored by scientists at Harvard and elsewhere.
You might also like
Genetic analysis reveals a culture enriched from both sides of the Danube.
Harvard researchers illuminate a longstanding epidemiological connection.
Harvard’s Faculty of Arts and Sciences broaches two tough topics.
More to explore
Expect massive job losses in industries associated with fossil fuels. The time to get ready is now.
A third-generation French baker on legacy loaves and the "magic" of baking
Generative AI can enhance teaching and learning but augurs a shift to oral forms of student assessment.